Psoriatic Disease

Welcome to this special edition of Healio Psoriatic Disease, which focusses on the management of psoriasis in patients with skin of color, coinciding with Black History Month.

Patients with nail psoriasis alongside psoriatic arthritis demonstrate worse disease activity, quality of life and work productivity than those without nail involvement, according to data published in The Journal of Rheumatology.

While novel drugs are changing the game in psoriatic arthritis, early diagnosis and interdisciplinary management remain keys to successful outcomes, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Secukinumab is effective in psoriatic arthritis at 6 and 12 months, with significantly better remission, low disease activity, retention and response rates in patients naïve to disease-modifying antirheumatic drugs, according to data.

A greater percentage of patients with psoriatic arthritis achieve remission with biologic therapy than those with rheumatoid arthritis, at both 1- and 12-year follow-up, according to data published in Arthritis Research & Therapy.

The National Psoriasis Foundation’s COVID-19 task force has updated its guidelines for managing psoriatic disease during the pandemic.

Healio launched Healio Psoriatic Disease in 2020, a publication dedicated to the coverage of psoriasis and psoriatic disease.

Treating psoriasis and psoriatic disease during the COVID-19 pandemic has proven to be challenging for many providers.

The doctor-patient relationship is evolving from a paternalistic to a collaborative model of care across the rheumatology specialty.

Upadacitinib, in doses of either 15 or 30 mg, is superior to placebo in improving signs and symptoms of active psoriatic arthritis among patients who are intolerant, or had an inadequate response, to a biologic DMARD, according to data.